Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dianthus Therapeutics filings document the regulatory record of a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. The company’s 8-K reports furnish operating and financial results, corporate presentations, clinical-program disclosures for claseprubart, FDA feedback on trial screening and safety-risk language, and updates tied to programs in neuromuscular and rheumatology indications.
Other filings cover capital-structure and governance matters, including common stock listed on the Nasdaq Capital Market, underwritten public offering agreements, pre-funded warrant terms, shareholder voting matters, proxy disclosure, material agreements, and equity-compensation actions. These records also describe risk-factor and forward-looking disclosure around clinical development, regulatory interactions, financing needs and public-company governance.
Dianthus Therapeutics ownership update: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial ownership of 2,611,733 shares of Common Stock, equal to 4.8%, reported as of March 31, 2026.
The filing states the Fund directly holds 2,611,733 shares, that the percentage is calculated using 54,448,771 shares outstanding as of March 30, 2026, and that RA Capital has been delegated voting and dispositive power over the Fund's holdings. The Reporting Persons disclaim group status and disclaim beneficial ownership for purposes described in the text.
Dianthus Therapeutics filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 643,599 shares of Common Stock, representing 1.2% of the class as of the close of business on March 31, 2026.
The filing identifies Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as the reporting persons; the shares are held through an investment fund managed by Point72 and are reported as shared voting and dispositive power. The percentage basis is an aggregate of 52,942,083 Shares outstanding derived from offering and prior outstanding counts disclosed in the filing.
Dianthus Therapeutics reported that Sirenia Capital Management and Alex Silverstein together hold 2,798,122 shares, representing 5.3% of the outstanding common stock. The filing states the outstanding share count used for the percentage was 52,942,083 shares (aggregate basis).
The reported position includes 500,000 shares issuable upon exercise of call options. The disclosure is made via a joint Schedule 13G filing under Rule 13d-1(k).
Dianthus Therapeutics, Inc. Schedule 13G/A filed by Wellington Management Group LLP and related entities reports beneficial ownership of 2,595,783 shares of common stock, representing 4.77% of the class. The filing attributes shared voting power of 2,358,243 and shared dispositive power of 2,595,783. The cover pages list the holdings across Wellington affiliates and identify the reporting structure of parent and adviser entities. The signatures show the filing was executed on 05/15/2026.
Dianthus Therapeutics ownership update: This Amendment No. 3 to a Schedule 13G/A states that Octagon-related reporting persons collectively beneficially own 1,946,667 shares of Dianthus Therapeutics common stock, equal to 3.6% of the class based on 54,448,771 shares outstanding as of March 30, 2026. The filing attributes shared voting and dispositive power over those shares to Octagon and identifies Octagon and affiliated funds as holders.
Dianthus Therapeutics director Paula Soteropoulos reported an exercise-and-sale of 599 shares of common stock. She exercised stock options to acquire 599 shares at $8.44 per share, then sold 599 shares in the open market at $85.47 per share on May 8, 2026.
The stock option related to 599 underlying shares and had an expiration date of June 6, 2032. A footnote states the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Dianthus Therapeutics reports a wider Q1 2026 loss alongside a transformative equity raise that greatly strengthens its balance sheet. The company posted a net loss of $40.8M, versus $29.5M a year earlier, as it increased research and development spending to $34.5M and general and administrative costs to $12.5M.
License revenue was modest at $0.5M, so operations remain largely funded by external capital. In March 2026, Dianthus completed a public offering of common stock and pre-funded warrants with gross proceeds of about $719.0M, and also raised $58.7M through an at-the-market program.
These financings drove cash, cash equivalents and short-term investments to approximately $1.11B, with total assets of $1.25B as of March 31, 2026. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date.
Dianthus Therapeutics reported a Q1 2026 net loss of $40.8 million, or $0.85 per share, as it increased investment in its autoimmune disease pipeline. License revenue was $0.5 million, while higher research and administrative costs continued to drive operating losses.
The company ended the quarter with approximately $1.2 billion in cash, cash equivalents and investments, supported by an upsized underwritten offering that generated about $719 million in gross proceeds, which it expects to fund operations into 2030. Management highlighted an early GO decision in the CAPTIVATE CIDP trial, Orphan Drug Designation for claseprubart in Myasthenia Gravis, and progress on the gMG Phase 3 program, the MMN Phase 2 trial, and the DNTH212 Phase 1 study and planned rheumatology indications.
BlackRock, Inc. reports beneficial ownership of 2,634,004 shares of Dianthus Therapeutics Common Stock, representing 5.1% of the class. The filing shows sole voting power for 2,582,959 shares and sole dispositive power for 2,634,004 shares as stated on the cover.
The filing identifies the holdings as held by certain Reporting Business Units of BlackRock, Inc. and is signed by a Managing Director on 04/27/2026.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.
The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.